α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders.

摘要

The present invention relates to a method of using a compound of the formula (I): wherein A, X<1>, X<2>, and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.